Polyunsaturated fatty acid-mediated inflammatory pathway modulation

"Inflammatory pathway modulation via polyunsaturated fatty acids" does not refer to a single molecular target but rather describes the broad set of mechanisms by which polyunsaturated fatty acids—notably omega‑3 (n‑3) and omega‑6 (n‑6) types—regulate inflammatory processes. PUFAs influence immunity by altering the synthesis of eicosanoids such as prostaglandins and leukotrienes; activating nuclear receptors like PPARs; changing cell membrane properties; suppressing pro-inflammatory cytokines; and generating specialized pro-resolving mediators including resolvins. These actions collectively impact diseases characterized by dysregulated inflammation—including autoimmune disorders, cardiovascular diseases, IBD, sepsis—and are the basis for therapeutic use or dietary recommendations involving fish oil or other PUFA-rich sources. However, because this is not a single protein/receptor/enzyme but an entire class/pathway involving many molecules across multiple families, it is not considered a canonical drug target. Note: This entry is not suitable as a canonical drug target because it refers to an entire biological process/pathway rather than an individual molecule or receptor that can be directly targeted by drugs.

Other names

PUFA-mediated immunomodulationPolyunsaturated fatty acid signaling in inflammationn-3 and n-6 polyunsaturated fatty acids in immune regulation

PUFAs modulate inflammation through several mechanisms: - Alteration of eicosanoid synthesis (prostaglandins, leukotrienes) - Activation of nuclear receptors such as peroxisome proliferator–activated receptors (PPARs) and liver X receptors - Modulation of cell membrane fluidity and lipid raft composition affecting immune cell signaling - Suppression of pro-inflammatory cytokine production - Generation of anti-inflammatory lipid mediators such as resolvins and protectins from EPA/DHA